Ad
FATE Quote Trading Chart Fate Therapeutics Inc.
home / stock / fate / fate quote
Quote | Fate Therapeutics Inc. (NASDAQ:FATE)
| Last: | $1.33 |
|---|---|
| Change Percent: | 1.49% |
| Open: | $1.32 |
| Close: | $1.33 |
| High: | $1.35 |
| Low: | $1.29 |
| Volume: | 1,065,594 |
| Last Trade Date Time: | 01/24/2025 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
FATE Last Twenty Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $1.33 | $1.32 | $1.33 | $1.35 | $1.29 | 1,065,594 | 01-24-2025 |
| $1.34 | $1.34 | $1.34 | $1.385 | $1.29 | 1,245,625 | 01-23-2025 |
| $1.34 | $1.33 | $1.34 | $1.37 | $1.28 | 2,461,457 | 01-22-2025 |
| $1.32 | $1.29 | $1.32 | $1.35 | $1.27 | 1,010,371 | 01-21-2025 |
| $1.27 | $1.28 | $1.27 | $1.3 | $1.24 | 1,271,294 | 01-20-2025 |
| $1.27 | $1.28 | $1.27 | $1.3 | $1.24 | 1,271,294 | 01-17-2025 |
| $1.25 | $1.32 | $1.25 | $1.32 | $1.22 | 1,683,357 | 01-16-2025 |
| $1.32 | $1.31 | $1.32 | $1.36 | $1.265 | 2,110,661 | 01-15-2025 |
| $1.255 | $1.31 | $1.255 | $1.31 | $1.04 | 4,359,907 | 01-14-2025 |
| $1.29 | $1.45 | $1.29 | $1.45 | $1.28 | 6,296,068 | 01-13-2025 |
| $1.465 | $1.62 | $1.465 | $1.625 | $1.4532 | 4,067,780 | 01-10-2025 |
| $1.67 | $1.73 | $1.67 | $1.75 | $1.63 | 1,685,805 | 01-09-2025 |
| $1.67 | $1.73 | $1.67 | $1.75 | $1.63 | 1,685,805 | 01-08-2025 |
| $1.75 | $1.85 | $1.75 | $1.91 | $1.72 | 1,799,675 | 01-07-2025 |
| $1.87 | $1.85 | $1.87 | $1.99 | $1.78 | 2,858,996 | 01-06-2025 |
| $1.8 | $1.82 | $1.8 | $1.86 | $1.735 | 1,874,746 | 01-03-2025 |
| $1.79 | $1.68 | $1.79 | $1.9 | $1.62 | 4,230,682 | 01-02-2025 |
| $1.65 | $1.62 | $1.65 | $1.66 | $1.59 | 3,014,004 | 01-01-2025 |
| $1.65 | $1.62 | $1.65 | $1.66 | $1.59 | 3,014,004 | 12-31-2024 |
| $1.62 | $1.6 | $1.62 | $1.63 | $1.55 | 2,392,920 | 12-30-2024 |
News, Short Squeeze, Breakout and More Instantly...
Fate Therapeutics Inc. Company Name:
FATE Stock Symbol:
NASDAQ Market:
Fate Therapeutics Inc. Website:
Ad
-
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Ther...
-
Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (&#x...
-
2024-11-29 09:44:38 ET Palantir Technologies Inc (PLTR) PLTR is trading UP for the last 5 days, and it at trading at $66.74 with volume of 13,633,565 and a one day change of $0.69 (1.04%). Palantir Technologies Inc has a 52-week low of 15.67 and a 52-week high of $67.88. The busines...